SJSmita Jauhari

Smita Jauhari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Smita Jauhari has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Highly diversified fluorinated chromane-thiadiazol-saturated cyclic amine hybrids: Design, synthesis, single crystal XRD and MCF-7 Cell-line Study

    by Bhavika Mohite, Bhadreshkumar K. Chabhadiya, Nishith Teraiya, Khushal Kapadiya, Ramavatar Meena, Aniruddhasinh Rana, Smita Jauhari


  • Assessment of novel 1,2,3,4-tetrahydroquinoline-triazole hybrids compounds as inhibitors of E. coli DNA GyraseB: in vitro and in silico investigation

    by Bhadreshkumar K. Chabhadiya, Hem N. Naik, Bhavika A. Mohite, Iqrar Ahmad, Harun Patel, Abdel-Basit Al-Odayni, Ramavatar Meena, Dhanji Rajani, Smita Jauhari

    Ten novel 1,2,3,4-tetrahydroquinolone-triazole compounds (denoted as 6a-6j) were synthesized using click chemistry. These compounds were thoroughly characterized using various analytical techniques, such as FT-IR, mass spectrometry,1H NMR, and 13C NMR. To gather a deeper understanding regarding structural properties of the synthesized compounds, we conducted Density Functional Theory (DFT) studies employing the B3LYP/6-311G (d,p) methodology. These calculations allowed us to evaluate important properties such as the HOMO-LUMO energy gap, chemical potential (µ), electrophilicity (ω), chemical hardness (η), dipole moment (Debye), and total energy (a.u.) for the synthesized hybrids. Moving on to the practical application of these hybrids, we evaluated in vitro antimicrobial inhibitory potential against two gram-positive and two gram-negative strains, and three fungal strains. Obtained outcomes revealed a range of antibacterial activity, with some compounds exhibiting excellent to moderate efficacy. Compounds 6b and 6i showed a very good result with a MIC of 12.5 μg/mL compared to standard Ciprofloxacin (MIC 25 μg/mL), demonstrating strong antibacterial activity against E. coli among the 6a-6j compounds. Furthermore, in silico docking validated our compounds' interaction with E. coli DNA gyrase B. Further, a 200 ns simulation revealed that the promising compounds maintained stability within the binding cavity, with RMSD values below 3 Å, and exhibited reduced structural fluctuations compared to the Apo protein, as evidenced by lower average RMSF values in the ligand-protein complexes. Additionally, an in silico ADME study assessed the drug-likeness of the hybrids, offering insights for future drug development.

  • Investigation of novel Tetrahydroisoquinoline derivatives as potent anti-lung cancer agents: In vitro and In silico studies

    by Bhadreshkumar K. Chabhadiya, Hem N. Naik, Bhavika A. Mohite, Mohit Agrawal, Mohamed F. AlAjmi, Abha Meena, Ramavatar Meena, Mohammad Rizwan Alam, Smita Jauhari


  • Design, Synthesis, and Antimicrobial Evaluation of Novel 5-Chloropyridine Oxalamide Conjugates as In Vitro and In Silico Inhibitors of E. coli DNA Gyrase and C. albicans Sterol 14α-Demethylase (CYP51)

    by Dilip C. Kanjariya, Hem N. Naik, Meet J. Sherashiya, Yogesh T. Naliapara, Dhanji Rajani, Smita Jauhari

    Objective: A series of novel 5-chloropyridine oxalamide conjugates (IVa–IVl) were designed, synthesized, and evaluated for their in vitro and in silico antimicrobial activity, compared with standard drugs. Methods: The coupling of 2-((5-chloropyridin-2-yl)amino)-2-oxoacetic acid (II) with various ethyl and methyl esters of amino acids (IIIa–IIIi), including glycine, L-histidine, L-alanine, L-phenylalanine, L-valine, and L-tryptophan, was carried out using DIPEA as a base and HATU as a coupling agent to obtain the final targeted 5-chloropyridine oxalamide conjugates (IVa–IVl). Antimicrobial screening was performed using the MTT assay. Further, all hybrids (IVa–IVl) were geometry-optimized using Gaussian09, molecular docking was performed using AutoDock Tool 1.5.7, and in silico ADME analysis was conducted via the online SwissADME server. Results and Discussion: The novel 5-chloropyridine oxalamide conjugates (IVa–IVl) were characterized by IR, 1H, 13C NMR spectroscopy, and mass spectrometry, and screened against two Gram-negative and two Gram-positive bacterial strains, as well as three fungal strains. Compounds methyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)glycinate (IVb), methyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)tryptophanate (IVe), and methyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)phenylalaninate (IVl) exhibited the most potent antibacterial activity against E. coli, with MIC values of 25 μg/mL. Compounds ethyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)glycinate (IVa), methyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)histidinate (IVc), and ethyl (2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)tryptophanate (IVd) exhibited the most potent antifungal activity against C. albicans with MIC values of 250 μg/mL. DFT analysis was performed using the B3LYP/6-311G(d,p) basis set to determine quantum chemical parameters, frontier molecular orbitals (FMO), and molecular electrostatic potential (MEP) of all synthesized compounds (IVa–IVl). Moreover, molecular docking studies revealed that compounds (IVa–IVl) could bind to the active sites of E. coli DNA gyrase (1KZN) and C. albicans sterol 14α-demethylase (CYP51) (5TZ1), forming hydrogen bonds with key active-site amino acid residues. Conclusions: The synthesized hybrids exhibited potent to moderate activity against Gram-positive and Gram-negative bacterial strains, as well as fungal pathogens. This was further supported by molecular docking and ADME analysis, suggesting their potential as promising lead compounds for the development of future antimicrobial drugs.

  • Design and Synthesis of Isatin‐1,2,3‐triazole Hybrids as Anticancer Agents

    by Bhavika Mohite, Bhadreshkumar K. Chabhadiya, Khushal M. Kapadiya, Vijay M. Khedkar, Smita Jauhari

    Isatin, a chemically defined indole‐1 H ‐2,3‐dione, is widely considered a desirable therapeutic fragment in the field of drug discovery. Similarly, the 1,2,3‐triazole ring is a major pharmacophore system among nitrogen containing heterocycles. Molecular hybrids comprising isatin and acyl azides functions linked by triazole rings were synthesized and tested for cytotoxic effects against sixty human cancer cell lines due to the drug resistance with most of the currently utilized anticancer medicines. The 1,2,3‐triazole‐isatin hybrids (8a–8j) were produced in high yields and with exceptional purity via Huisgen's 1,3‐dipolar cycloaddition involving acyl azide, 7a–7j , and an Isatin‐based N ‐alkyne 3 in the presence of water as the principal solvent and n ‐Bu‐OH and DMF as cosolvents. compounds 8c , 8g , and 8h showed highly effective growth inhibition against breast, leukemia, and melanoma cell lines, with mortality ranging from 6% to 99% and PGI = >70% in the majority of instances. While 8a and 8b showed weak to moderate action against all the tested cancer cell line and few compounds 8d , 8f , 8i, and 8j shows low activity. A molecular docking study against cyclin‐dependent kinase (CDK2) could provide insights into the mechanistic basis of antitumor activity.


  • Design, Synthesis, and Evaluation of Quinoline‐1,2,3‐Triazole Hybrids as CYP51 Inhibitors: In Silico Study and In Vitro Antimicrobial Assessment

    by Bhadreshkumar K. Chabhadiya, Hem N. Naik, Bhavika A. Mohite, Iqrar Ahmad, Yogesh Naliapara, Dhanji Rajani, Mohd Sajid Ali, Harun Patel, Smita Jauhari

    Novel Quinoline‐triazole hybrid derivatives ( 9 a – 9 l ) were designed and synthesized via click reaction methodology to develop lead compounds with good antibacterial and antifungal potency. Synthetic compounds have been characterized using 1 H NMR, 13 C NMR, and mass spectrum analysis. In‐vitro antibacterial activity against two gram‐positive and two gram‐negative strains and in‐vitro antifungal activity against three different strains were performed for the synthesized compounds. Compounds 9 a , 9 d , and 9 i exhibited potent inhibition activity against S. aureus ranging from MIC=12.5–50 μg/mL, and compounds 9 a , 9 c , 9 d , 9 e , 9 f , 9 j , and 9 l exhibited potent inhibition activity against C. albicans fungal strains ranging from MFC=250–500 μg/mL. Molecular docking study of C. albicans Sterol 14α‐demethylase (CYP51) protein (PDB ID:5TZ1) and S. aureus tyrosyl‐tRNA synthetase (PDB ID: 1JIJ) was performed to understand the mechanism of action through which these derivatives work. In silico studies of Hybrid 9 d demonstrated strong hydrogen bonding and π–π interactions with Tyr64, Phe233, and Phe228 in line with the co‐crystals SB‐239629 and VT1161 exhibiting favorable interactions that inhibits both bacterial and fungal strains.


  • Open Access

    LC–MS profiling, in vitro and in silico C-ABL kinase inhibitory approach to identify potential anticancer agents from Dalbergia sissoo leaves

    by Hem N. Naik, Dilip Kanjariya, Shahnaz Parveen, Iqrar Ahmed, Abha Meena, Harun Patel, Ramavatar Meena, Smita Jauhari

    Belonging to the Fabaceae family, Dalbergia sissoo, a versatile plant, has gained prominence for its potent medicinal attributes, especially antipyretic, anti-inflammatory, and cardioprotective properties, as well as the use of its leaf juice in cancer treatment. Despite these recognized applications by natives and tribals, comprehensive insight into its biological activities and chemical composition remains limited. This study aimed to explore the cytotoxic potential of sequentially extracted leaf extracts from Dalbergia sissoo using various solvents, aiming to unveil the array of phytochemicals through LC–MS profiling. Among the extracts evaluated, the extract employing methanol:water extracting media (HN-2) appeared with the most remarkable results in both phytochemical diversity and biological activity. Furthermore, in vitro results of HN-2's in vitro anticancer efficacy were confirmed through in silico molecular docking and molecular dynamics simulation. These analyses demonstrated its ability to inhibit C-ABL kinase within leukemia K562 cells, directing that Dalbergia sissoo leaves serve as a bioactive agent reservoir. Consequently, this suggests that the Dalbergia sissoo plant is a potential source of bioactive compounds that can be used as a precursor for developing new cancer inhibitors, mainly targeting leukemia.